申请人:Zeng Qingping
公开号:US20120270877A1
公开(公告)日:2012-10-25
The invention provides compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
该发明提供了在体内直接抑制IRE-1α活性的化合物、前药和药学上可接受的盐。这些化合物和前药对于治疗与未折叠蛋白反应相关的疾病是有用的,可以作为单一药物或联合治疗使用。